Reflux hyphema from transient hypotony after Ozurdex® in eyes with prior GATT [PDF]
American Journal of Ophthalmology Case Reports, 2023 Purpose: To report on delayed-onset hyphema following intravitreal injection of dexamethasone implant Ozurdex® in eyes with a history of gonioscopy-assisted transluminal trabeculotomy (GATT).
Rebecca E. Tanenbaum +2 more
doaj +2 more sources
Modified insertion technique for a sustained-release dexamethasone intravitreal implant (Ozurdex®) [PDF]
American Journal of Ophthalmology Case Reports, 2020 Purpose: We describe a modified injection technique that adheres a sustained-release dexamethasone intravitreal implant (Ozurdex®) to the vitreous base.
Daniel H. Lee, Clement K. Chan
doaj +2 more sources
Acute retinal necrosis following dexamethasone intravitreal implant (Ozurdex®) administration in an immunocompetent adult with a history of HSV encephalitis: a case report [PDF]
BMC Ophthalmology, 2020 Background Dexamethasone intravitreal implants (0.7 mg) (Ozurdex®, Allergan Inc., Madison, NJ) are FDA approved for managing macular oedema (ME) of retinal vein occlusion (RVO).
Zhi-Yong Zhang, Xiu-Yun Liu, Tao Jiang
doaj +2 more sources
Fractured dexamethasone implant (OZURDEX®) following intravitreal injection [PDF]
Oman Journal of Ophthalmology, 2021 Dexamethasone implant (Ozurdex™) is a relatively safe medication with few adverse events can happen. We demonstrate clinical course and images of a rare case of fractured intravitreal Ozurdex™ implant that observed immediately following injection and its
Saud M Aljohani +2 more
doaj +2 more sources
Intravitreal dexamethasone implant (Ozurdex®) findings over time: ultrasound and ultra-widefield fundus photography [PDF]
International Journal of Retina and VitreousBackground Ozurdex® (Allergan®, AbbVie Company, North Chicago, Illinois, EUA), is composed of 0.7 mg of dexamethasone, fused in a solid biodegradable PLGA polymer, whose degradation occurs naturally in the vitreous cavity, usually in six months after its
Gabriela Assumpção Brito Pereira Pellegrini +2 more
doaj +2 more sources
Intralenticular Ozurdex® – One Year Later [PDF]
Case Reports in Ophthalmology, 2017 Reported here is a case of intralenticular sustained-release dexamethasone implant (Ozurdex®, Allergan, Irvine, CA, USA) present for 1 year with effective treatment of refractory diabetic macular edema without rapid cataract formation.
Kathleen A. Regan +3 more
doaj +2 more sources
Adult Coats’ Disease Successfully Managed with the Dexamethasone Intravitreal Implant (Ozurdex®) Combined with Retinal Photocoagulation [PDF]
Case Reports in Ophthalmology, 2012 Purpose: To report a case of Coats’ disease managed with the dexamethasone intravitreal implant Ozurdex® (Allergan, Inc., Irvine, Calif., USA) combined with retinal photocoagulation.
Sebastián Martínez-Castillo +4 more
doaj +2 more sources
A New Side Effect of Intravitreal Dexamethasone Implant (Ozurdex®) [PDF]
Case Reports in Ophthalmological Medicine, 2017 Dexamethasone implant, 0,7 mg (Ozurdex, Allergan, Inc., Irvine, CA, USA), is drug mostly used in the treatment of the diabetic macular edema and edema related to retinal vein occlusion.
Erdem Eris +5 more
doaj +2 more sources
Iatrogenic subretinal injection of Ozurdex® implant and its effect on macular edema [PDF]
Oman Journal of Ophthalmology, 2017 PURPOSE: The purpose of this study was to report a rare case of subretinal lodgement of Ozurdex® implant (Allergan Inc., Irvine, CA, USA) and its effect on macular edema in a case of central retinal vein occlusion (RVO).
Smita Shriram Karandikar +4 more
doaj +2 more sources
Outcomes of intravitreal dexamethasone implant (Ozurdex®) in patients with post-surgical macular edema – a real-world scenario [PDF]
International Journal of Retina and VitreousBackground Clinically significant macular edema (CME) is the leading cause of visual loss after ophthalmologic surgery due to the release of inflammatory mediators promoted by the procedures.
Elder Ohara de Oliveira Júnior +3 more
doaj +2 more sources